Immunovant, Inc.
IMVT
Hisse Senetlerindeki Sıralama
#3089
Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase,... Immunovant, Inc. is a biopharmaceutical firm in the clinical development phase, dedicated to advancing novel monoclonal antibody therapies for the treatment of various autoimmune conditions. The company's primary focus is batoclimab, a pioneering, fully human monoclonal antibody. This antibody is engineered to specifically target and block the neonatal fragment crystallizable receptor (FcRn), a key mechanism in certain autoimmune diseases. Batoclimab is currently undergoing Phase IIa clinical evaluations for treating both myasthenia gravis and thyroid eye disease. Additionally, it has commenced Phase II clinical studies for patients suffering from warm autoimmune hemolytic anemia. Established in 2018, Immunovant operates from its headquarters in New York, New York, functioning as a subsidiary under the umbrella of Roivant Sciences Ltd.
Hisse Fiyatı
$28.31
Piyasa Değeri
$5.85B
Değişim (1 gün)
-0.98%
Değişim (1 yıl)
47.22%
Ülke
US
Ticaret Immunovant, Inc. (IMVT)
Kategori
Healthcare
Immunovant, Inc. (IMVT) için temettü verimi geçmişi
Immunovant, Inc. (hisse sembolü: IMVT) temettü verimi (TTM) 2026 itibariyle: 0
Son 5 yılın ortalama temettü verimi: 0.00%
Son 5 yılın ortalama temettü verimi: 0.00%
Immunovant, Inc. (IMVT) için 2026 - 2026 arası temettü verimi geçmişi
Her yılın sonunda temettü verimi (TTM)
| Yıl | Temettü Verimi | Değiştir |
|---|---|---|
| Sağlanan tarihler için yeterli veri yok. | ||
Benzer şirketler veya rakiplerin temettü verimi (TTM)
| Şirket | Temettü Verimi | Ülke |
|---|---|---|
| 0.00% |
US
|
|
| 0.00% |
US
|
|
| 2.17% |
AU
|
|
| 0.00% |
NL
|
|
| 0.00% |
CH
|
